Peer reviewed
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
The Lancet: Diabetes & Endocrinology (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
The Lancet: Diabetes & EndocrinologyAccessed Aug 5, 2026
Registry record
Source metadata
- Publisher
- The Lancet: Diabetes & Endocrinology
- Source type
- Peer reviewed
- Registry ID
pubmed-sustain2-2017- DOI
- 10.1016/S2213-8587(17)30092-X
- PMID
- 28385659
Source usage
Not yet linked from a public content page
This record may be retained for an upcoming review or for internal source normalization.
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.